Skip to main content

Table 5 Biochemical failure prognostic factors

From: Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity

Characteristics

Bivariate analysis

Multivariate analysis

HR and 95% CI

p-value

HR and 95% CI

p-value

Agea

 ≤70

1

   

 >70

1.21 [0.69; 2.13]

0.49

-

-

Stage

 T1c + 2a

1

   

 T2b

1.88 [0.91; 3.89]

0.09

  

 T2c-T4

2.11 [1.11; 4.03]

0.02

  

D’Amico Risk groupa

 Low

0.11 [0.01; 0.79]

0.03

0.09 [0.01; 0.69]

0.02

 Intermediate

0.57 [0.32; 0.99]

0.04

0.49 [0.28; 0.88]

0.02

 High

1

   

% Positive biopsya

 ≥50%

1.72 [0.98; 3.05]

0.06

-

-

 <50

1

   

Gleason

 6

1

   

 3 + 4

2.39 [0.92; 6.24]

0.07

  

 4 + 3

5.04 [1.99; 12.72]

<0.01

  

 8–10

3.56 [1.32; 9.65]

0.01

  

PSA baseline

 <10

1

   

 10–20

1.03 [0.53; 2]

0.92

  

 >20

2.71 [1.38; 5.34]

<0.01

  

Androgen deprivation

 No

1

   

 <6m

1.15 [0.59; 2.25]

0.66

  

 ≥6m

1.33 [0.66; 2.69]

0.42

  

RTH total dose

 70 Gy

1

   

 74 Gy

2.56 [0.61;10.70]

0.20

  

 80 Gy

1.59 [0.36;7.05)

0.54

  

RTH total dosea

    

 70-74Gy

1

   

 80 Gy

0.67 [0.36; 1.25]

0.21

-

-

Nadira

 <0.2

1

   

 ≥0.2

1.52 [0.86; 2.68]

0.15

1.79 [1.01; 3.21]

0.04

  1. Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, PSA prostate specific antigen, RTH radiation therapy
  2. aParameters included in backward multivariate analysis
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us